Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Phillips

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Neurology|November 15, 2006
Infusion-related hypersensitivity reactions during natalizumab treatmentJ T Phillips, P W O'Connor, E Havrdova, et al.
Archives of Neurology|September 15, 2005
Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directionsE M Frohman, M Filippi, O Stuve, et al.
Neurology|September 10, 2003
The utility of MRI in suspected MS [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyE M Frohman, D S Goodin, P A Calabresi, et al.
Neurology|April 25, 2007
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD H Miller, D Soon, K T Fernando, et al.
Neurology|November 7, 2008
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyO Stüve, P D Cravens, E M Frohman, et al.
Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.
Neurology|April 18, 2007
Natalizumab reduces visual loss in patients with relapsing multiple sclerosisL J Balcer, S L Galetta, P A Calabresi, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Neurology|November 15, 2006
Infusion-related hypersensitivity reactions during natalizumab treatmentJ T Phillips, P W O'Connor, E Havrdova, et al.
Archives of Neurology|September 15, 2005
Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directionsE M Frohman, M Filippi, O Stuve, et al.
Neurology|September 10, 2003
The utility of MRI in suspected MS [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyE M Frohman, D S Goodin, P A Calabresi, et al.
Neurology|April 25, 2007
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD H Miller, D Soon, K T Fernando, et al.
Neurology|November 7, 2008
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyO Stüve, P D Cravens, E M Frohman, et al.
Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.
Neurology|April 18, 2007
Natalizumab reduces visual loss in patients with relapsing multiple sclerosisL J Balcer, S L Galetta, P A Calabresi, et al.
Pageof 3